stockrowInsmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
Follow INSM
Alert me
Insmed, Inc. (INSM) Return on invested capital
Insmed, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −247.6%, down 247.6 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −645.6% (fiscal 2018) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 633.88 |
| FY2023 | −633.9% | (331.60) |
| FY2022 | −302.3% | (216.84) |
| FY2021 | −85.4% | 59.77 |
| FY2020 | −145.2% | (31.86) |
| FY2019 | −113.4% | 532.27 |
| FY2018 | −645.6% | (312.65) |
| FY2017 | −333.0% | (100.82) |
| FY2016 | −232.2% | (96.07) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| EXEL Exelixis, Inc. compare | 66.6% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 59.4% |
| INCY Incyte Corporation compare | 21.6% |
| ASND Ascendis Pharma A/S compare | 15.1% |
| GMAB Genmab A/S Sponsored ADR compare | 6.99% |
| BBIO BridgeBio Pharma, Inc. compare | 0.00% |
| BNTX BioNTech SE Sponsored ADR compare | −34.3% |
| ROIV Roivant Sciences Ltd. compare | −34.5% |
| INSM Insmed, Inc. | −247.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on INSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement